» Articles » PMID: 33256119

'There and Back Again'-Forward Genetics and Reverse Phenotyping in Pulmonary Arterial Hypertension

Overview
Journal Genes (Basel)
Publisher MDPI
Date 2020 Dec 1
PMID 33256119
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Although the invention of right heart catheterisation in the 1950s enabled accurate clinical diagnosis of pulmonary arterial hypertension (PAH), it was not until 2000 when the landmark discovery of the causative role of bone morphogenetic protein receptor type II () mutations shed new light on the pathogenesis of PAH. Since then several genes have been discovered, which now account for around 25% of cases with the clinical diagnosis of idiopathic PAH. Despite the ongoing efforts, in the majority of patients the cause of the disease remains elusive, a phenomenon often referred to as "missing heritability". In this review, we discuss research approaches to uncover the genetic architecture of PAH starting with forward phenotyping, which in a research setting should focus on stable intermediate phenotypes, forward and reverse genetics, and finally reverse phenotyping. We then discuss potential sources of "missing heritability" and how functional genomics and multi-omics methods are employed to tackle this problem.

Citing Articles

Leaving no patient behind! Expert recommendation in the use of innovative technologies for diagnosing rare diseases.

van Karnebeek C, ODonnell-Luria A, Baynam G, Baudot A, Groza T, Jans J Orphanet J Rare Dis. 2024; 19(1):357.

PMID: 39334316 PMC: 11438178. DOI: 10.1186/s13023-024-03361-0.


Pulmonary Arterial Hypertension and TGF-β Superfamily Signaling: Focus on Sotatercept.

Stump B, Waxman A BioDrugs. 2024; 38(6):743-753.

PMID: 39292393 DOI: 10.1007/s40259-024-00680-3.


Reverse Phenotyping after Whole-Exome Sequencing in Children with Developmental Delay/Intellectual Disability-An Exception or a Necessity?.

Ilic N, Maric N, Maver A, Armengol L, Kravljanac R, Cirkovic J Genes (Basel). 2024; 15(6).

PMID: 38927725 PMC: 11203244. DOI: 10.3390/genes15060789.


A Bioinformatic Algorithm based on Pulmonary Endoarterial Biopsy for Targeted Pulmonary Arterial Hypertension Therapy.

Rothman A, Mann D, Nunez J, Tarmidi R, Restrepo H, Sarukhanov V Open Respir Med J. 2024; 17:e187430642308160.

PMID: 38655076 PMC: 11037516. DOI: 10.2174/18743064-v17-230927-2023-9.


Discovery of novel genetic syndromes in Latin America: Opportunities and challenges.

Faundes V, Repetto G, Valdivia L Genet Mol Biol. 2024; 47Suppl 1(Suppl 1):e20230318.

PMID: 38466870 PMC: 10964411. DOI: 10.1590/1678-4685-GMB-2023-0318.


References
1.
Yu Y, Keller S, Remillard C, Safrina O, Nicholson A, Zhang S . A functional single-nucleotide polymorphism in the TRPC6 gene promoter associated with idiopathic pulmonary arterial hypertension. Circulation. 2009; 119(17):2313-22. PMC: 2749566. DOI: 10.1161/CIRCULATIONAHA.108.782458. View

2.
Durrington H, Upton P, Hoer S, Boname J, Dunmore B, Yang J . Identification of a lysosomal pathway regulating degradation of the bone morphogenetic protein receptor type II. J Biol Chem. 2010; 285(48):37641-9. PMC: 2988369. DOI: 10.1074/jbc.M110.132415. View

3.
Lange A, Haitchi H, LeCras T, Sridharan A, Xu Y, Wert S . Sox17 is required for normal pulmonary vascular morphogenesis. Dev Biol. 2014; 387(1):109-20. PMC: 4422074. DOI: 10.1016/j.ydbio.2013.11.018. View

4.
Culley M, Chan S . Mitochondrial metabolism in pulmonary hypertension: beyond mountains there are mountains. J Clin Invest. 2018; 128(9):3704-3715. PMC: 6118596. DOI: 10.1172/JCI120847. View

5.
Kang H, Louie J, Weisman A, Sheu-Gruttadauria J, Davis-Dusenbery B, Lagna G . Inhibition of microRNA-302 (miR-302) by bone morphogenetic protein 4 (BMP4) facilitates the BMP signaling pathway. J Biol Chem. 2012; 287(46):38656-64. PMC: 3493910. DOI: 10.1074/jbc.M112.390898. View